Core Insights - Artelo Biosciences, Inc. is focused on developing treatments for cancer, pain, dermatologic, and neurological conditions through modulation of lipid-signaling pathways, with multiple clinical milestones expected in 2025 [2][11] Business Highlights - The Phase 1 study of ART26.12, a Fatty Acid Binding Protein (FABP) inhibitor, is progressing rapidly and is expected to conclude in Q2 2025 [2][6] - Initial data from the Phase 2 CAReS study of ART27.13 in cancer anorexia is anticipated in Q2 2025, with promising safety and efficacy observed in earlier studies [2][6][8] - ART12.11, a CBD-TMP cocrystal targeting anxiety and depression, is set to begin clinical trials in 2H 2025 [2][6] Financial Results - Research and development expenses for the year ended December 31, 2024, were 5.7 million in 2023 [7] - General and administrative expenses were 4.2 million in 2023 [7] - The net loss for the year ended December 31, 2024, was 3.05 per share, compared to a net loss of 3.14 per share in 2023 [7] Product Development - ART26.12 is being developed as a non-opioid, non-steroidal analgesic for chemotherapy-induced peripheral neuropathy (CIPN) [4] - ART27.13 is a once-daily oral agent targeting peripheral CB1 and CB2 receptors, with potential benefits for cancer patients experiencing weight loss and appetite issues [5][10] - ART12.11 has shown improved pharmacokinetics and efficacy compared to other CBD forms, with a patent enforceable until December 10, 2038 [9]
Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results